We protect your health through science
Investigation
AIDS Immunopathology
Publications
High SARS-CoV-2 viral load and low CCL5 expression levels in the upper respiratory tract are associated with COVID-19 severity.
Pérez-García F, Martin-Vicente M, Rojas-García RL, Castilla-García L, Muñoz-Gomez MJ, Hervás Fernández I, González Ventosa V, Vidal-Alcántara EJ, Cuadros-González J, Bermejo-Martin JF, Resino S#, Martínez I#. High SARS-CoV-2 viral load and low CCL5 expression levels in the upper respiratory tract are associated with COVID-19 severity. J Infect Dis. 2022 Mar 15;225(6):977-982. doi: 10.1093/infdis/jiab604. PMID: 34910814 (A; FI= 7.759; Q1 Microbiology; JCR 2021).
PUBMEDNeighborhood environmental factors linked to hospitalizations of older people for viral lower respiratory tract infections in Spain: a case-crossover study.
Álvaro-Meca A, Sepúlveda-Crespo D#, Resino R, Ryan P, Martínez I#, Resino S#. Neighborhood environmental factors linked to hospitalizations of older people for viral lower respiratory tract infections in Spain: a case-crossover study. Environ Health. 2022 Nov 8;21(1):107. doi: 10.1186/s12940-022-00928-x. PMID: 36348411.
PUBMEDDiagnostic Performance of the HCV Core Antigen Test To Identify Hepatitis C in HIV-Infected Patients: a Systematic Review and Meta-Analysis.
Sepúlveda-Crespo D, Treviño-Nakoura A, Bellon JM, Jiménez-Sousa MA, Ryan P, Martínez I#, Fernández-Rodríguez A#, Resino S#. Diagnostic Performance of the HCV Core Antigen Test To Identify Hepatitis C in HIV-Infected Patients: a Systematic Review and Meta-Analysis. J Clin Microbiol. 2023 Jan 26; 61(1):e0133122. doi: 10.1128/jcm.01331-22. PMID: 36537787.
PUBMEDHCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients.
Brochado-Kith Ó, Martínez I*, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S*. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Front Immunol. 2021 Aug 23;12:723196. doi: 10.3389/fimmu.2021.723196. eCollection 2021.PMID: 34497613 (A; FI= 8.786; Q1 Immunology; JCR 2021).
PUBMEDAdditional Information
The AIDS Immunopathology Unit has been coordinated since 2000 by Dr. José Alcamí, bringing together during its history more than 20 independent researchers who collaboratively study different aspects of HIV infection. During this years, more than 30 visiting researchers and more than 50 national and international students have passed through the unit. From the beginning of the year 2025, Javier García Pérez and Francisco Díez Fuertes assumed the coordination of the AIDS Immunopathology Unit, with the aim of projecting its scientific competitiveness following multidisciplinary approaches and through the maintenance of the current close collaborations, as well as the promotion of participation in new national and international research networks.
Historically, the current members of the unit have focused on different lines of basic research that include the study of antibodies and the development of vaccines against HIV-1, the study of viral entry and tropism of the virus or the study of the host through the genomic characterization of populations with an extreme phenotype. Currently, the activity of our unit in the field of HIV-1 is focused on three main lines:
1. Mecanismos moleculares asociados a la protección de la infección por VIH-1 en pacientes con distrofia muscular de cinturas dominante D2 (LGMDD2).
2. Generación de anticuerpos neutralizantes de uso terapéutico basados en la respuesta neutralizante de amplio espectro frente a virus fundadores.
3. Cribado y caracterización de nuevos fármacos anti-latencia frente al VIH-1.
A partir del año 2020, nuestra unidad se vuelca con la investigación sobre COVID-19, participando y liderando diferentes proyectos de investigación aplicada y clínica. Fruto de esta fuerte implicación en el campo, en la actualidad se mantienen diferentes estudios sobre la caracterización de la respuesta inmune frente a SARS-CoV-2, integrando diferentes técnicas de virología molecular, estrategias de inteligencia epidemiológica y tecnologías de célula única.
We also participate in different research consortiums and networks, such as the Spanish AIDS Research Network or the Center for Biomedical Research in Infectious Diseases Network (CIBER-INFEC), in which we participate as researchers in different lines and work packages within the research programs “Global Health, emerging and re-emerging infections” as well as “HIV/AIDS and sexually transmitted infections”.
Supervised doctoral theses
1. GENOMIC AND FUNCTIONAL ANALYSIS OF HIV-1 PROTECTION PARAMETERS IN PATIENTS WITH SLOW PROGRESSION OF INFECTION.
Student: Erick de la Torre Tarazona.
Supervisors: José Alcamí and Francisco Díez Fuertes.
Academic entity: Universidad Autónoma de Madrid.
Defense date: July 14th, 2020.
2. ANALYSIS OF MIARN EXPRESSION PROFILES AND FUNCTIONAL CHARACTERIZATION IN HIV-POSITIVE INDIVIDUALS WITH DIFFERENT PROGRESSION TO AIDS.
Student: Rubén Ayala Suárez.
Supervisors: José Alcamí and Francisco Díez Fuertes.
Academic entity: Universidad de Alcalá.
Defense date: June 12nd, 2023.
The AIDS Immunopathology Unit has been coordinated since 2000 by Dr. José Alcamí, bringing together during its history more than 20 independent researchers who collaboratively study different aspects of HIV infection. During this years, more than 30 visiting researchers and more than 50 national and international students have passed through the unit. From the beginning of the year 2025, Javier García Pérez and Francisco Díez Fuertes assumed the coordination of the AIDS Immunopathology Unit, with the aim of projecting its scientific competitiveness following multidisciplinary approaches and through the maintenance of the current close collaborations, as well as the promotion of participation in new national and international research networks.
Historically, the current members of the unit have focused on different lines of basic research that include the study of antibodies and the development of vaccines against HIV-1, the study of viral entry and tropism of the virus or the study of the host through the genomic characterization of populations with an extreme phenotype. Currently, the activity of our unit in the field of HIV-1 is focused on three main lines:
1. Mecanismos moleculares asociados a la protección de la infección por VIH-1 en pacientes con distrofia muscular de cinturas dominante D2 (LGMDD2).
2. Generación de anticuerpos neutralizantes de uso terapéutico basados en la respuesta neutralizante de amplio espectro frente a virus fundadores.
3. Cribado y caracterización de nuevos fármacos anti-latencia frente al VIH-1.
A partir del año 2020, nuestra unidad se vuelca con la investigación sobre COVID-19, participando y liderando diferentes proyectos de investigación aplicada y clínica. Fruto de esta fuerte implicación en el campo, en la actualidad se mantienen diferentes estudios sobre la caracterización de la respuesta inmune frente a SARS-CoV-2, integrando diferentes técnicas de virología molecular, estrategias de inteligencia epidemiológica y tecnologías de célula única.
We also participate in different research consortiums and networks, such as the Spanish AIDS Research Network or the Center for Biomedical Research in Infectious Diseases Network (CIBER-INFEC), in which we participate as researchers in different lines and work packages within the research programs “Global Health, emerging and re-emerging infections” as well as “HIV/AIDS and sexually transmitted infections”.
Supervised doctoral theses
1. GENOMIC AND FUNCTIONAL ANALYSIS OF HIV-1 PROTECTION PARAMETERS IN PATIENTS WITH SLOW PROGRESSION OF INFECTION.
Student: Erick de la Torre Tarazona.
Supervisors: José Alcamí and Francisco Díez Fuertes.
Academic entity: Universidad Autónoma de Madrid.
Defense date: July 14th, 2020.
2. ANALYSIS OF MIARN EXPRESSION PROFILES AND FUNCTIONAL CHARACTERIZATION IN HIV-POSITIVE INDIVIDUALS WITH DIFFERENT PROGRESSION TO AIDS.
Student: Rubén Ayala Suárez.
Supervisors: José Alcamí and Francisco Díez Fuertes.
Academic entity: Universidad de Alcalá.
Defense date: June 12nd, 2023.